Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

NCT05338346 is registered in ClinicalTrials.gov with Antengene Discovery Limited as lead sponsor.

NCT NCT05338346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05338346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
Lead sponsor
Antengene Discovery Limited
Phase
Phase 1
Overall status
Terminated
Start date
July 8, 2022
Completion date
January 8, 2024
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, hematological malignancies